Martin Bergstrand, Ph.D.

Principal Consultant & MIDD Platform Scientific Lead

Portrait-of-Martin-Bergstrand_Pharmetheus

Bio

  • Co-founded Pharmetheus in 2012, actively working in client projects, serving as MIDD Platform Scientific Lead
  • Expertise includes trial design, pharmacometrics (especially complex pharmacokinetics, mechanism based PKPD and Markov models), and model informed drug development in therapeutic areas such as infectious, metabolic, and cardiovascular diseases
  • Previously worked as part-time Researcher at Uppsala University, Sweden, where he performed pharmacometric research primarily by supervision of Ph.D. students, as Visiting Scientist at Mahidol-Oxford Tropical Medicine Research Unit, Thailand, and Clinical Pharmacology Scientist at AstraZeneca R&D Mölndal, Sweden
  • M.Sc. in Biomedicine (2003) from University of Kalmar, Sweden, and Ph.D. in Pharmaceutical Biosciences (2011) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

A tutorial on pharmacometric Markov modelsThe reference corrected VPC (rcVPC) – an informative model diagnostics for assessing underying exposure-response relationshipsPhase 1 interim population PK/PD modeling and recommended phase 2 dose exploration for IMM-1-104: A novel concept oral deep cyclic inhibitor of MEKA workflow for comparing drug candidates based on Probability of Pharmacological Success (PoPS)Population pharmacokinetics of survodutide in subjects with overweight or obesity with and without Type 2 Diabetes Mellitus based on Phase I and Phase II dataThe reference corrected VPC – A more intuitive model diagnosticA workflow for evaluating and optimizing the designs of paediatric studiesConcentration-QTcF Analysis of Quizartinib in Patients With Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)Exploring the relationship between BI 456906 exposure and change in fasting plasma glucose, fasting serum insulin, and glycated hemoglobin (HbA1c) using population PKPD modelingModel-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modelingTowards Industrialisation of Probability of Pharmacological Success (PoPS)